MRSHMarsh & McLennan Companies, Inc.
Marsh & McLennan Companies, Inc. (MRSH) is a global insurance broker and risk management firm that sells insurance and reinsurance services to businesses and individuals. The company’s next catalyst is October 22, 2026 — Q3 2026 Earnings Release, which will test its ability to deliver consistent top-line growth and margin expansion amid a shifting market.
- The company generates $28.33B in revenue, with a net margin of 15.4% and free cash flow of $3.83B over the last twelve months.
- It operates with a negative debt-to-equity ratio of -5.06x, suggesting strong balance sheet flexibility.
- Shareholders’ equity is -$3.92B, but the company has historically generated positive free cash flow, which supports its dividend and strategic reinvestment.
The schedule
- Thu22Oct
The Q3 2026 earnings release is a significant event for MRSH, as it will provide insight into the company's financial performance and updated 2026 outlook. This report is expected to influence investor sentiment and stock price movement, with the potential for both positive and negative market reactions. The outcome of this event could have a substantial impact on the stock's trajectory in the coming weeks, making it a key moment for market participants to monitor closely. The earnings report will be closely watched by analysts and investors alike, as it may signal the company's health and future prospects in the Insurance - Brokers sector.
- Mon8Feb
- Thu22Apr
- Thu22Jul
Past
- Tue21Jul
Actual outcome: Mixed · $183.31 at outcome
Marsh & McLennan delivered a solid Q2 2026 earnings report, featuring a 6% increase in revenue to $7.4 billion and a 5% rise in adjusted operating income. The top-line growth, fueled by strength in the Consulting and Risk & Insurance Services units, along with strategic investments in AI, outweighed concerns over margin pressures and ultimately drove the stock to surpass the bull target.
Marsh & McLennan delivered a solid Q2 2026 earnings report, featuring a 6% increase in revenue to $7.4 billion and a 5% rise in adjusted operating income. The top-line growth, fueled by strength in the Consulting and Risk & Insurance Services units, along with strategic investments in AI, outweighed concerns over margin pressures and ultimately drove the stock to surpass the bull target.
- Thu16Apr
Actual outcome: Bear · $170.15 at outcome
Marsh & McLennan reported Q1 2026 EPS of $2.37, exactly matching consensus estimates. Despite the in-line earnings, the stock fell 6.8% as the updated 2026 outlook failed to provide the upside surprise investors were anticipating. The lack of a definitive beat or raised forward guidance ultimately pressured shares lower in the near term.
Marsh & McLennan reported Q1 2026 EPS of $2.37, exactly matching consensus estimates. Despite the in-line earnings, the stock fell 6.8% as the updated 2026 outlook failed to provide the upside surprise investors were anticipating. The lack of a definitive beat or raised forward guidance ultimately pressured shares lower in the near term.
- Mon9Feb
Actual outcome: Mixed · $175.83 at outcome
MRSH reported Q4 2025 EPS of $1.69, exactly matching consensus estimates. Delivering in-line results reassured investors of the company's stable execution and lack of negative surprises, prompting a modest initial 2.7% gain. This steady fundamental performance provided the foundation for continued momentum, ultimately driving the stock well past the $182 bull target in the ensuing months.
MRSH reported Q4 2025 EPS of $1.69, exactly matching consensus estimates. Delivering in-line results reassured investors of the company's stable execution and lack of negative surprises, prompting a modest initial 2.7% gain. This steady fundamental performance provided the foundation for continued momentum, ultimately driving the stock well past the $182 bull target in the ensuing months.